{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:18:43Z","timestamp":1790957923417,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30-AG066511"],"award-info":[{"award-number":["P30-AG066511"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.mcna.2024.10.003","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T02:01:24Z","timestamp":1731981684000},"page":"463-483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Alzheimer\u2019s Disease Diagnosis and Management in the Age of Amyloid Monoclonal Antibodies"],"prefix":"10.1016","volume":"109","author":[{"given":"Chadwick M.","family":"Hales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mcna.2024.10.003_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mcna.2024.10.003_bib2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.mcna.2024.10.003_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.mcna.2018.10.009","article-title":"The Alzheimer's disease clinical spectrum: diagnosis and management","volume":"103","author":"Atri","year":"2019","journal-title":"Med Clin North Am"},{"issue":"1","key":"10.1016\/j.mcna.2024.10.003_bib4","doi-asserted-by":"crossref","first-page":"e12334","DOI":"10.1002\/dad2.12334","article-title":"Alzheimer's disease diagnosis and management: perspectives from around the world","volume":"14","author":"Kerwin","year":"2022","journal-title":"Alzheimers Dement (Amst)"},{"issue":"16","key":"10.1016\/j.mcna.2024.10.003_bib5","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jama.2019.4782","article-title":"Diagnosis and management of dementia: review","volume":"322","author":"Arvanitakis","year":"2019","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.mcna.2024.10.003_bib6","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1212\/CON.0000000000001132","article-title":"Management of dementia","volume":"28","author":"Carlsson","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"issue":"2","key":"10.1016\/j.mcna.2024.10.003_bib7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1017\/cjn.2017.267","article-title":"The worried well? Characteristics of cognitively normal patients presenting to a rural and remote memory clinic","volume":"45","author":"Verity","year":"2018","journal-title":"Can J Neurol Sci"},{"issue":"3","key":"10.1016\/j.mcna.2024.10.003_bib8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","article-title":"Mild cognitive impairment as a diagnostic entity","volume":"256","author":"Petersen","year":"2004","journal-title":"J\u00a0Intern Med"},{"issue":"3","key":"10.1016\/j.mcna.2024.10.003_bib9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.mcna.2024.10.003_bib10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer's disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Mol Neurodegener"},{"issue":"5","key":"10.1016\/j.mcna.2024.10.003_bib11","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0002-9440(10)64448-3","article-title":"Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau","volume":"161","author":"DeTure","year":"2002","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.mcna.2024.10.003_bib12","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/brain\/awab431","article-title":"Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies","volume":"145","author":"Poggiolini","year":"2022","journal-title":"Brain"},{"issue":"15","key":"10.1016\/j.mcna.2024.10.003_bib13","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/jama.2024.0792","article-title":"Skin biopsy detection of phosphorylated alpha-synuclein in patients with synucleinopathies","volume":"331","author":"Gibbons","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.mcna.2024.10.003_bib14","first-page":"33","article-title":"Comorbidity and polypharmacy in people with dementia: insights from a large, population-based cross-sectional analysis of primary care data","volume":"46","author":"Clague","year":"2017","journal-title":"Age Ageing"},{"issue":"1","key":"10.1016\/j.mcna.2024.10.003_bib15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.mcna.2024.10.003_bib16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2174\/1567205015666180119092427","article-title":"Estimating Alzheimer's disease progression rates from normal cognition through mild cognitive impairment and stages of dementia","volume":"15","author":"Davis","year":"2018","journal-title":"Curr Alzheimer Res"},{"issue":"4","key":"10.1016\/j.mcna.2024.10.003_bib17","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2174\/156720511795745348","article-title":"Asymptomatic Alzheimer's disease: a prodrome or a state of resilience?","volume":"8","author":"Driscoll","year":"2011","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"10.1016\/j.mcna.2024.10.003_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/archneurol.2011.31","article-title":"Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment","volume":"68","author":"Wilson","year":"2011","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.mcna.2024.10.003_bib19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/archneur.1995.00540250089017","article-title":"Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease","volume":"52","author":"Bierer","year":"1995","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.mcna.2024.10.003_bib20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13195-023-01314-6","article-title":"Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants","volume":"15","author":"Dubois","year":"2023","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"10.1016\/j.mcna.2024.10.003_bib21","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"Alzheimer's disease facts and figures","volume":"20","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.mcna.2024.10.003_bib22","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/BF02866241","article-title":"Uber eigenartige Krankheitsfaelle des spaeteren Alters","volume":"4","author":"Alzheimer","year":"1911","journal-title":"Zeitschrift fuer die gesamte Neurologie und Psychiatrie"},{"issue":"6","key":"10.1016\/j.mcna.2024.10.003_bib23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ca.980080612","article-title":"An English translation of Alzheimer's 1907 paper, \"Uber eine eigenartige Erkankung der Hirnrinde\"","volume":"8","author":"Alzheimer","year":"1995","journal-title":"Clin Anat"},{"issue":"Pt 12","key":"10.1016\/j.mcna.2024.10.003_bib24","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1093\/brain\/awv316","article-title":"Alzheimer's disease in the 100 years since Alzheimer's death","volume":"138","author":"Ryan","year":"2015","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.mcna.2024.10.003_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27061816","article-title":"Role of cholinergic signaling in Alzheimer's disease","volume":"27","author":"Chen","year":"2022","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.mcna.2024.10.003_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","article-title":"The cholinergic hypothesis of Alzheimer's disease: a review of progress","volume":"66","author":"Francis","year":"1999","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.mcna.2024.10.003_bib27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1212\/WNL.0000000000000596","article-title":"Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis","volume":"83","author":"Ryman","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.mcna.2024.10.003_bib28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"10","key":"10.1016\/j.mcna.2024.10.003_bib29","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1093\/brain\/awad159","article-title":"The amyloid cascade hypothesis: an updated critical review","volume":"146","author":"Kepp","year":"2023","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.mcna.2024.10.003_bib30","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1474-4422(16)00063-6","article-title":"Dementia in Down's syndrome","volume":"15","author":"Ballard","year":"2016","journal-title":"Lancet Neurol"},{"issue":"5123","key":"10.1016\/j.mcna.2024.10.003_bib31","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.mcna.2024.10.003_bib32","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","article-title":"New insights into the genetic etiology of Alzheimer's disease and related dementias","volume":"54","author":"Bellenguez","year":"2022","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.mcna.2024.10.003_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"10248","key":"10.1016\/j.mcna.2024.10.003_bib34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mcna.2024.10.003_bib35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer's disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"10.1016\/j.mcna.2024.10.003_bib36","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.mayocp.2017.02.011","article-title":"Alzheimer disease: scientific breakthroughs and translational challenges","volume":"92","author":"Caselli","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1016\/j.mcna.2024.10.003_bib37","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1001\/jamaneurol.2014.1358","article-title":"Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography","volume":"71","author":"Palmqvist","year":"2014","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.mcna.2024.10.003_bib38","doi-asserted-by":"crossref","first-page":"e12314","DOI":"10.1002\/dad2.12314","article-title":"Clinical application of CSF biomarkers for Alzheimer's disease: from rationale to ratios","volume":"14","author":"Bouwman","year":"2022","journal-title":"Alzheimers Dement (Amst)"},{"issue":"6","key":"10.1016\/j.mcna.2024.10.003_bib39","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/practneurol-2019-002468","article-title":"Amyloid PET imaging in clinical practice","volume":"20","author":"Kolanko","year":"2020","journal-title":"Pract Neurol"},{"issue":"4","key":"10.1016\/j.mcna.2024.10.003_bib40","doi-asserted-by":"crossref","first-page":"a006171","DOI":"10.1101\/cshperspect.a006171","article-title":"The neuropsychological profile of Alzheimer disease","volume":"2","author":"Weintraub","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"10.1016\/j.mcna.2024.10.003_bib41","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1212\/CON.0000000000001082","article-title":"Atypical Alzheimer disease variants","volume":"28","author":"Polsinelli","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"issue":"3","key":"10.1016\/j.mcna.2024.10.003_bib42","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1474-4422(20)30440-3","article-title":"New insights into atypical Alzheimer's disease in the era of biomarkers","volume":"20","author":"Graff-Radford","year":"2021","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.mcna.2024.10.003_bib43","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1038\/s41380-023-02215-8","article-title":"The use of neuroimaging techniques in the early and differential diagnosis of dementia","volume":"28","author":"Chouliaras","year":"2023","journal-title":"Mol Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2024.10.003_bib44","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.2967\/jnumed.121.263194","article-title":"(18)F-FDG PET imaging in neurodegenerative dementing disorders: insights into subtype classification, emerging disease categories, and mixed dementia with copathologies","volume":"63","author":"Minoshima","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"10","key":"10.1016\/j.mcna.2024.10.003_bib91","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1046\/j.1532-5415.2003.51465.x","article-title":"The Mini-Cog as a screen for dementia: validation in a population-based sample","volume":"51","author":"Borson","year":"2003","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.mcna.2024.10.003_bib92","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"issue":"18","key":"10.1016\/j.mcna.2024.10.003_bib93","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1001\/jama.1993.03500180078038","article-title":"Population-based norms for the Mini-Mental State Examination by age and educational level","volume":"269","author":"Crum","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2024.10.003_bib94","unstructured":"Website citation for St. Louis Mental Status Exam. Available at: https:\/\/www.slu.edu\/medicine\/internal-medicine\/geriatric-medicine\/aging-successfully\/assessment-tools\/mental-status-exam.php (Accessed 4 November 2024)."},{"issue":"10","key":"10.1016\/j.mcna.2024.10.003_bib95","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"issue":"9","key":"10.1016\/j.mcna.2024.10.003_bib96","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"issue":"1","key":"10.1016\/j.mcna.2024.10.003_bib97","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0022-3956(82)90033-4","article-title":"Development and validation of a geriatric depression screening scale: a preliminary report","volume":"17","author":"Yesavage","year":"1982","journal-title":"J Psychiatr Res"},{"issue":"3","key":"10.1016\/j.mcna.2024.10.003_bib98","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/geronj\/37.3.323","article-title":"Measurement of functional activities in older adults in the community","volume":"37","author":"Pfeffer","year":"1982","journal-title":"J Gerontol"},{"issue":"2","key":"10.1016\/j.mcna.2024.10.003_bib99","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.dadm.2015.03.003","article-title":"THE QUICK DEMENTIA RATING SYSTEM (QDRS): A RAPID DEMENTIA STAGING TOOL","volume":"1","author":"Galvin","year":"2015","journal-title":"Alzheimers Dement (Amst)"},{"issue":"11","key":"10.1016\/j.mcna.2024.10.003_bib100","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.mcna.2024.10.003_bib45","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","article-title":"Frequent amyloid deposition without significant cognitive impairment among the elderly","volume":"65","author":"Aizenstein","year":"2008","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.mcna.2024.10.003_bib46","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ana.21904","article-title":"Cognition, reserve, and amyloid deposition in normal aging","volume":"67","author":"Rentz","year":"2010","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.mcna.2024.10.003_bib47","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s43587-024-00599-y","article-title":"Disease staging of Alzheimer's disease using a CSF-based biomarker model","volume":"4","author":"Salvado","year":"2024","journal-title":"Nat Aging"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2024.10.003_bib48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40120-017-0073-9","article-title":"A\u00a0review of fluid biomarkers for Alzheimer's disease: moving from CSF to blood","volume":"6","author":"Blennow","year":"2017","journal-title":"Neurol Ther"},{"issue":"1","key":"10.1016\/j.mcna.2024.10.003_bib49","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13195-022-01117-1","article-title":"The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review","volume":"14","author":"Brand","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.mcna.2024.10.003_bib50","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","article-title":"Advantages and disadvantages of the use of the CSF Amyloid beta (Abeta) 42\/40 ratio in the diagnosis of Alzheimer's Disease","volume":"11","author":"Hansson","year":"2019","journal-title":"Alzheimers Res Ther"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2024.10.003_bib51","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.2967\/jnumed.121.263195","article-title":"The role of amyloid PET in imaging neurodegenerative disorders: a review","volume":"63","author":"Chapleau","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"10","key":"10.1016\/j.mcna.2024.10.003_bib53","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","article-title":"Quantification of amyloid PET for future clinical use: a state-of-the-art review","volume":"49","author":"Pemberton","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.mcna.2024.10.003_bib54","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests","volume":"30","author":"Barthelemy","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.mcna.2024.10.003_bib55","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 Immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.mcna.2024.10.003_bib56","first-page":"2053","article-title":"Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort","volume":"271","author":"Mendes","year":"2024","journal-title":"J\u00a0Neurol"},{"issue":"2","key":"10.1016\/j.mcna.2024.10.003_bib57","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/alz.13542","article-title":"Plasma Abeta42\/Abeta40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease","volume":"20","author":"Rissman","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.mcna.2024.10.003_bib58","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","article-title":"The role of apolipoprotein E in Alzheimer's disease","volume":"63","author":"Kim","year":"2009","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.mcna.2024.10.003_bib59","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13195-024-01513-9","article-title":"Diagnostic performance of plasma pTau(217), pTau(181), Abeta(1-42) and Abeta(1-40) in the LUMIPULSE automated platform for the detection of Alzheimer disease","volume":"16","author":"Arranz","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"10.1016\/j.mcna.2024.10.003_bib60","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1002\/alz.13455","article-title":"The potential clinical value of plasma biomarkers in Alzheimer's disease","volume":"19","author":"Blennow","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.1016\/j.mcna.2024.10.003_bib61","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1532-5415.1993.tb06738.x","article-title":"Effects of age, gender and education on selected neuropsychological tests in an elderly community cohort","volume":"41","author":"Wiederholt","year":"1993","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.mcna.2024.10.003_bib62","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cortex.2014.07.019","article-title":"Anosognosia in Alzheimer's disease: diagnosis, frequency, mechanism and clinical correlates","volume":"61","author":"Starkstein","year":"2014","journal-title":"Cortex"},{"issue":"3","key":"10.1016\/j.mcna.2024.10.003_bib63","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1212\/CON.0000000000001131","article-title":"Alzheimer disease","volume":"28","author":"McDade","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"issue":"1","key":"10.1016\/j.mcna.2024.10.003_bib64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40120-022-00416-x","article-title":"Non-drug therapies for Alzheimer's disease: a review","volume":"12","author":"Li","year":"2023","journal-title":"Neurol Ther"},{"issue":"7","key":"10.1016\/j.mcna.2024.10.003_bib66","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults","volume":"71","year":"2023","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"3","key":"10.1016\/j.mcna.2024.10.003_bib89","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ajcnut.2023.12.011","volume":"119","author":"Vyas","year":"2024","journal-title":"Am J Clin Nutr"},{"issue":"9","key":"10.1016\/j.mcna.2024.10.003_bib67","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2024.10.003_bib68","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fnmol.2020.00137","article-title":"Targeting amyloidogenic processing of APP in Alzheimer's disease","volume":"13","author":"Zhao","year":"2020","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"10.1016\/j.mcna.2024.10.003_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/molpharm.123.000726","article-title":"Passive immunotherapies targeting amyloid-beta in Alzheimer's disease: a quantitative systems pharmacology perspective","volume":"105","author":"Markovic","year":"2023","journal-title":"Mol Pharmacol"},{"issue":"4","key":"10.1016\/j.mcna.2024.10.003_bib70","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mcna.2024.10.003_bib71","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer's disease","volume":"378","author":"Honig","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mcna.2024.10.003_bib72","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd","year":"2022","journal-title":"J\u00a0Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.mcna.2024.10.003_bib76","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3233\/JAD-215699","article-title":"Alzheimer's disease: key insights from two decades of clinical trial failures","volume":"87","author":"Kim","year":"2022","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.mcna.2024.10.003_bib77","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J\u00a0Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.mcna.2024.10.003_bib78","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer's disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"10.1016\/j.mcna.2024.10.003_bib79","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1001\/jamaneurol.2014.681","article-title":"Clinical predictors of severe cerebral amyloid angiopathy and influence of APOE genotype in persons with pathologically verified Alzheimer disease","volume":"71","author":"Ringman","year":"2014","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.mcna.2024.10.003_bib90","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2174\/1573403X11666150805115822","article-title":"Left Atrial Appendage Closure -The WATCHMAN Device","volume":"11","author":"Akinapelli","year":"2015","journal-title":"Curr Cardiol Rev"},{"issue":"5","key":"10.1016\/j.mcna.2024.10.003_bib80","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMc2215148","article-title":"Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke","volume":"388","author":"Reish","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mcna.2024.10.003_bib81","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"10.1016\/j.mcna.2024.10.003_bib82","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","article-title":"Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer's disease therapeutics","volume":"83","author":"Cummings","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.mcna.2024.10.003_bib83","first-page":"3637954","article-title":"Physician perceptions about the barriers to prompt diagnosis of mild cognitive impairment and Alzheimer's disease","volume":"2019","author":"Judge","year":"2019","journal-title":"Int J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.mcna.2024.10.003_bib84","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/jgs.17690","article-title":"The Georgia Memory Net: implementation of a statewide program to diagnose and treat Alzheimer's disease and related dementias","volume":"70","author":"Bender","year":"2022","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.mcna.2024.10.003_bib85","author":"Liu"},{"key":"10.1016\/j.mcna.2024.10.003_bib86","doi-asserted-by":"crossref","first-page":"104030","DOI":"10.1016\/j.jbi.2022.104030","article-title":"Applications of artificial intelligence to aid early detection of dementia: a scoping review on current capabilities and future directions","volume":"127","author":"Li","year":"2022","journal-title":"J\u00a0Biomed Inform"},{"issue":"2","key":"10.1016\/j.mcna.2024.10.003_bib87","doi-asserted-by":"crossref","first-page":"e2355800","DOI":"10.1001\/jamanetworkopen.2023.55800","article-title":"Artificial intelligence assistive software tool for automated detection and quantification of amyloid-related imaging abnormalities","volume":"7","author":"Sima","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.mcna.2024.10.003_bib88","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of solanezumab in preclinical Alzheimer's disease","volume":"389","author":"Sperling","year":"2023","journal-title":"N\u00a0Engl J Med"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712524001299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712524001299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:41:34Z","timestamp":1762213294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712524001299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0025712524001299"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2024.10.003","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alzheimer\u2019s Disease Diagnosis and Management in the Age of Amyloid Monoclonal Antibodies","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2024.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}